OPPDATERING Hematologi / Onkologi 2024
ESMO-kongressen 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Du bruker en eldre versjon av nettleseren din, så enkelte funksjoner vises kanskje ikke riktig.
MINIMALE Krav: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 forbedrer rPFS for metastatisk kastrasjonsresistente prostatakreftpasienter som er taxan-naive 23. okt 2023 PSMAfore-studiens funn er begrenset av det faktum at de ikke viser en fordel i forhold til OS.
Registrer deg for billetter eller stander
Stedskart og hoteller rundt
Munich - Holiday Inn Munich - Sentrum, Bayern, Tyskland Munich - Holiday Inn Munich - Sentrum, Bayern, Tyskland
Bli medlem!